2020 marked the first year the Office of New Drugs (OND) developed an Annual Report. This report offers readers insight into OND’s priorities through a message from the Director, a review of the COVID-19 response and lessons learned, an overview of the Office’s reorganization and the accomplishments of the clinical and nonclinical offices within OND, as well as the Office’s plans and priorities heading into 2021.

• 2020 Office of New Drugs Annual Report (PDF - 18 MB)